Previous 10 | Next 10 |
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released financial results for the full year ending Dec. 31, 2023; the company also reported on corp...
Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially pivotal GBM study Berubicin study enrollment completed; Topline data expected in first half of 2025 Clinical progress...
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in two April investor conferences, including the MedInvest Biotech & Pharma Investo...
HOUSTON, TX / ACCESSWIRE / April 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John ...
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...
Recent research has identified processes that could lead to the growth of tumors. The research was conducted by a team at the University of Plymouth’s Brain Tumour Research Centre , led by Dr. Claudia Barros. This institution is focused on providing new understanding of certain groups ...
CNS Pharmaceuticals recently appointed Amy Mahery, a biotech commercialization leader, to its Board of Directors Ms. Mahery brings over 20 years’ experience, having worked with small and large companies, and has held diverse commercial leadership roles in the U.S. and globally The comp...
Figures show that brain cancer occurs in less than 1% of the population in America. At least one-third of individuals diagnosed with primary brain cancer tumors survive for at least five years. Those with glioblastoma, a common type of brain cancer, have about a 14% chance of living an addition...
Brain tumors, which affects thousands of individuals around the globe, can be diagnosed using various imaging techniques , including magnetic resonance imaging (MRI) and computed tomography (CT) scans. Some tumors cannot be diagnosed using these techniques, however, which makes it hard for them ...
A look at the top 10 most actives in the United States Remark Holdings Inc. (MARK) rose 264.4% to $1.25 on volume of 238,216,008 shares Advanced Micro Devices Inc. (AMD) fell 3.2% to $172.06 on volume of 122,265,677 shares Phunware Inc. (PHUN) fell 1.0% to $0.2893 on volume of 119,416,884...
News, Short Squeeze, Breakout and More Instantly...
CNS Pharmaceuticals Inc. Company Name:
CNSP Stock Symbol:
NYSE Market:
CNS Pharmaceuticals Inc. Website:
New research suggests that cancer may have been plaguing individuals even thousands of years ago. Researchers at the University of Cambridge’s Duckworth Laboratory Collection studied skulls obtained from Ancient Egypt, observing lesions which they believe may have been left by malignant t...
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured in tomorrow’s Virtual Investor Closing Bell Series. According to the announcemen...
Live video webcast with Chief Executive Officer, John Climaco, on Wednesday, June 17 th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / July 16, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatm...